



Market Announcement

16 January 2020

Amplia Therapeutics Limited (ASX: ATX) – Trading Halt

Description

The securities of Amplia Therapeutics Limited ('ATX') will be placed in trading halt at the request of ATX, pending it releasing an announcement regarding a capital raise. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 20 January 2020 or when the announcement is released to the market.

Issued by

Maria Clemente

Adviser, Listings Compliance (Sydney)

Mr. Corey Lian
Adviser, Listings Compliance (Sydney)
Australian Securities Exchange

16 January 2020

corey.lian@asx.com.au

&

tradinghaltssydney@asx.com.au

REQUEST FOR TRADING HALT

Amplia Therapeutics Limited (ASX Code: ATX) requests a Trading Halt in the securities of the Company.

For the purposes of Listing Rule 17.1 , ATX provides the following information:

- a) The Trading Halt is to allow the Company to undertake a capital raising process.
- b) The Company requests its securities remain in a trading halt for up to two days to resume trading on Monday 20 January 2020.
- c) The event which the Company expects will end the trading halt will be the lodgement of an announcement regarding the capital raising.
- d) The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely,



Andrew J Cooke
Directors and Company Secretary

About Amplia Therapeutics Limited

Amplia Therapeutics is a biopharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) small molecule inhibitors to address serious unmet medical needs in cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a development focus in pancreatic and ovarian cancer. FAK may also play a significant biological role in the progression of chronic fibrotic diseases, such as hepatic fibrosis and idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics is listed on the Australian Securities Exchange (ASX.ATX). For information about Amplia Therapeutics and its pipeline, please visit our website at www.ampliatx.com